Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Recruiting Phase 2 Interventional Study
MALT Lymphoma of Stomach Helicobacter Pylori Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
160 (estimated)
Sponsor
Fudan University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Histologically confirmed gastric mucosa-associated lymphoid tissue (MALT) lymphoma; * Current infection with Helicobacter pylori (Hp): Diagnosis can be made if any of the following criteria are met: a) Positive result in at least one of the following: RUT …
Contacts

Yizhen Liu, M.D., Ph.D.

021-64175590

aliuyz@126.com

CONTACT